Estrella Immunopharma (ESLA) announced that the company has regained compliance with the listing requirements of Nasdaq. This confirmation follows the company’s efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESLA: